VC Money Tight? Here’s How Startups Still Land Top Talent (2025) скачать в хорошем качестве

VC Money Tight? Here’s How Startups Still Land Top Talent (2025)

FDA layoffs, biotech hiring freezes, and AI-first drug discovery: executive recruiter William Holodnak explains how founders can hire biotech CEOs, de-risk Series-B boards, and attract AI drug-discovery talent in 2025. ⚡ WHAT YOU’LL LEARN Executive recruiter William Holodnak (ex-Fidelity, global biotech headhunter) breaks down 2025’s wild hiring market—and how founders can still build A-teams. In this episode you’ll learn: Why the April-1 FDA layoffs could delay approvals—and open new career doors for ex-regulators. The three traits VCs demand in first-time biotech CEOs during a funding slump. How AI-driven platforms like Isomorphic Labs raised mega-rounds in a down market. Immunology’s surge and why oncology startups are pivoting. Board-level recruiting tactics that de-risk your Series B. Chapter markers: 00:00 Intro 05:45 Cambridge—“the Florence of Biotech” origin story 08:20 FDA layoffs: threat or opportunity? 13:30 Biotech venture capital mood swings & funding checkpoints 18:00 What VCs really screen for in scientific founders 25:05 The “horses for courses” CEO model explained 33:00 Hot therapeutic areas: AI drug discovery, immunology, repurposing 38:30 Why boards need operators, not just investors 47:00 Career improvisation: William’s closing advice